Are There Challenges in Targeting the ER in Cancer Therapy?
While targeting the ER and UPR pathways holds promise, there are significant challenges. One major issue is the potential for toxicity to normal cells, which also rely on these pathways for protein homeostasis. Another challenge is the heterogeneity of tumors, which may lead to variable responses to ER-targeted therapies. Additionally, the development of resistance mechanisms by cancer cells can limit the effectiveness of these treatments.
